|Bid||9.87 x 1400|
|Ask||9.88 x 2200|
|Day's Range||9.80 - 10.00|
|52 Week Range||8.96 - 19.84|
|Beta (3Y Monthly)||0.27|
|PE Ratio (TTM)||16.45|
|Earnings Date||Nov 8, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.67|
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 60.00% and -2.76%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
CINCINNATI, Ohio, July 30, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter and first nine months ended June 30, 2019..
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CINCINNATI, July 10, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report third quarter 2019.
OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis technology for cannabinoid-based pharmaceuticals to treat severe diseases, today announced the appointment of Catherine Sazdanoff , JD, to its Board of Directors. Ms. Sazdanoff joins InMed's Board with 35 years of experience in the healthcare industry.
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc. (NASDAQ:VIVO) was in […]
Meridian Bioscience has completed a cash acquisition of a Canadian provider of molecular diagnostic instruments and assays.
CINCINNATI, June 03, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has.
Today we are going to look at Meridian Bioscience, Inc. (NASDAQ:VIVO) to see whether it might be an attractive...
Why Planet 13 Stock Fell ~6.8% on May 7(Continued from Prior Part)Valuation multipleThe increase in Planet 13 Holdings (PLTH) (PLNHF) stock price since the beginning of 2019 has led to a rise in its valuation multiple. As of May 7, the company was
One of Greater Cincinnati’s largest public companies is planning an acquisition that could have a price tag of up to $120 million.
Meridian Bioscience, Inc. today announced financial results for the second quarter and first six months ended March 31, 2019.
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 26.67% and 0.46%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has entered into a definitive agreement to acquire the business of GenePOC Inc., a Quebec City, Quebec, Canada based provider of molecular diagnostic instruments and assays. Founded in 2007, GenePOC has approximately 100 employees and generated total revenues of less than $1 million in calendar 2018. Meridian has agreed to make a cash payment at closing of the transaction of $50 million with future payments totaling up to an additional $70 million contingent upon the successful achievement of certain technical development milestones and sales thresholds.
On a per-share basis, the Cincinnati-based company said it had profit of 17 cents. Earnings, adjusted for costs related to mergers and acquisitions and non-recurring costs, were 19 cents per share. The ...
Does the April share price for Meridian Bioscience, Inc. (NASDAQ:VIVO) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then discounting them to today's val...